262 related articles for article (PubMed ID: 16403588)
1. Gastroretentive dosage forms: overview and special case of Helicobacter pylori.
Bardonnet PL; Faivre V; Pugh WJ; Piffaretti JC; Falson F
J Control Release; 2006 Mar; 111(1-2):1-18. PubMed ID: 16403588
[TBL] [Abstract][Full Text] [Related]
2. Gastroretentive dosage forms.
Moës AJ
Crit Rev Ther Drug Carrier Syst; 1993; 10(2):143-95. PubMed ID: 8370085
[TBL] [Abstract][Full Text] [Related]
3. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems.
Pawar VK; Kansal S; Garg G; Awasthi R; Singodia D; Kulkarni GT
Drug Deliv; 2011 Feb; 18(2):97-110. PubMed ID: 20958237
[TBL] [Abstract][Full Text] [Related]
4. Gastric retentive drug-delivery systems.
Hwang SJ; Park H; Park K
Crit Rev Ther Drug Carrier Syst; 1998; 15(3):243-84. PubMed ID: 9699081
[TBL] [Abstract][Full Text] [Related]
5. Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy.
Ishak RA; Awad GA; Mortada ND; Nour SA
J Control Release; 2007 Jun; 119(2):207-14. PubMed ID: 17412443
[TBL] [Abstract][Full Text] [Related]
6. Gastroretentive microparticles for drug delivery applications.
Adebisi A; Conway BR
J Microencapsul; 2011; 28(8):689-708. PubMed ID: 21726124
[TBL] [Abstract][Full Text] [Related]
7. Lectin conjugated gastroretentive multiparticulate delivery system of clarithromycin for the effective treatment of Helicobacter pylori.
Jain SK; Jangdey MS
Mol Pharm; 2009; 6(1):295-304. PubMed ID: 19093870
[TBL] [Abstract][Full Text] [Related]
8. [Gastroretentive dosage forms].
Kiss D; Zelkó R
Acta Pharm Hung; 2005; 75(3):169-76. PubMed ID: 16318241
[TBL] [Abstract][Full Text] [Related]
9. Formualtion and evaluation of floating drug delivery system containing clarithromycin for Helicobacter pylori.
Patel SS; Ray S; Thakur RS
Acta Pol Pharm; 2006; 63(1):53-61. PubMed ID: 17515330
[TBL] [Abstract][Full Text] [Related]
10. Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.
Zhao S; Lv Y; Zhang JB; Wang B; Lv GJ; Ma XJ
World J Gastroenterol; 2014 Jul; 20(28):9321-9. PubMed ID: 25071326
[TBL] [Abstract][Full Text] [Related]
11. Overview on gastroretentive drug delivery systems for improving drug bioavailability.
Lopes CM; Bettencourt C; Rossi A; Buttini F; Barata P
Int J Pharm; 2016 Aug; 510(1):144-58. PubMed ID: 27173823
[TBL] [Abstract][Full Text] [Related]
12. Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori.
Umamaheshwari RB; Jain S; Bhadra D; Jain NK
J Pharm Pharmacol; 2003 Dec; 55(12):1607-13. PubMed ID: 14738585
[TBL] [Abstract][Full Text] [Related]
13. Floating mucoadhesive alginate beads of amoxicillin trihydrate: A facile approach for H. pylori eradication.
Dey SK; De PK; De A; Ojha S; De R; Mukhopadhyay AK; Samanta A
Int J Biol Macromol; 2016 Aug; 89():622-31. PubMed ID: 27177460
[TBL] [Abstract][Full Text] [Related]
14. An Overview on Various Approaches and Recent Patents on Gastroretentive Drug Delivery Systems.
Kumar M; Kaushik D
Recent Pat Drug Deliv Formul; 2018; 12(2):84-92. PubMed ID: 29521255
[TBL] [Abstract][Full Text] [Related]
15. A novel gastroretentive porous microparticle for anti-Helicobacter pylori therapy: preparation, in vitro and in vivo evaluation.
Hao S; Wang Y; Wang B; Zou Q; Zeng H; Chen X; Liu X; Liu J; Yu S
Int J Pharm; 2014 Mar; 463(1):10-21. PubMed ID: 24406672
[TBL] [Abstract][Full Text] [Related]
16. Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of
de Souza MPC; de Camargo BAF; Spósito L; Fortunato GC; Carvalho GC; Marena GD; Meneguin AB; Bauab TM; Chorilli M
Crit Rev Microbiol; 2021 Aug; 47(4):435-460. PubMed ID: 33725462
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori: an overview on antimicrobials and drug delivery systems for its eradication.
El-Zahaby SA; Kassem AA; El-Kamel AH
Curr Drug Deliv; 2014; 11(3):306-12. PubMed ID: 24678600
[TBL] [Abstract][Full Text] [Related]
18. Compressed collagen sponges as gastroretentive dosage forms: in vitro and in vivo studies.
Gröning R; Cloer C; Georgarakis M; Müller RS
Eur J Pharm Sci; 2007 Jan; 30(1):1-6. PubMed ID: 17101267
[TBL] [Abstract][Full Text] [Related]
19. Formulation strategies for absorption windows.
Davis SS
Drug Discov Today; 2005 Feb; 10(4):249-57. PubMed ID: 15708743
[TBL] [Abstract][Full Text] [Related]
20. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease.
Jang EJ; Park SW; Park JS; Park SJ; Hahm KB; Paik SY; Sin MK; Lee ES; Oh SW; Park CY; Baik HW
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S278-85. PubMed ID: 19120912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
